Tuesday, December 1, 2020
Home Clinical Data Management ECOG Performance Status

ECOG Performance Status

ECOG Performance Status-scale was developed by Eastern Cooperative Oncology Group. Now this group is a part of ECOG-ACRIN Cancer Research Group.
This scale was published in 1982.

Importance of ECOG performance status:

  • It provides standard criteria to measure the impact of disease on patient’s daily living abilities/performances for example, ability to walk, Office work etc.
  • It helps sponsor to recruit Desired population in oncology studies.
  • It also provides considerable information about treatment effect on patient’s level of functioning.
  • Data Manager can get the information about this while reviewing the protocol in oncology trials as all protocol clearly mentions which performance Grading system needs to be used. (other performance Grading System: Karnofsky Performance Status)
  • Please refer the below table which is taken from ECOG-ACRIN Cancer Research Group website
GradeECOG Performance Status
0Fully active, able to carry on all pre-disease performance without any restriction
1Restricted in the physically strenuous activity but ambulatory and able to carry out work of the light or sedentary nature, e.g., light house work, office work
2Ambulatory and capable of all selfcare but not able to carry out any work activities; up and about more than 50% of waking hours
3Capable of only limited selfcare; confined to bed or chair more than 50% of the waking hours
4Completely disabled; cannot carry on any selfcare; totally confined to the bed or chair

Source: https://ecog-acrin.org/resources/ecog-performance-status

- Advertisement -


  1. Hey there. I found your blog via Google at the same time as looking for a related matter, your site got here up. It appears great. I have bookmarked it in my google bookmarks to come back then.


Please enter your comment!
Please enter your name here

8 + sixteen =

Most Popular

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

November 30, 2020: Eisai and Wren Therapeutics announced that the companies have entered into an exclusive research collaboration agreement aiming to advance...

AstraZeneca agreed to sell rights to Crestor to be divested to Grünenthal in Europe

December 01, 2020: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the...

AstraZeneca’sForxiga approved in Japan for chronic heart failure

November 30, 2020: AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving...

Moderna Announces the EC Approval for Initial 80 Million Doses of mRNA Vaccine Against COVID-19

November 25, 2020: "Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines...